Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Population variation in VKORC1 haplotype structure.

× No keyword cloud information.

18 in total

Review 1. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors: Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal: Chest Date: 2012-02 Impact factor: 9.410

2. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors: Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal: Pharmacogenomics Date: 2008-05 Impact factor: 2.533

Review 3. The future of warfarin pharmacogenetics in under-represented minority groups.

Authors: Larisa H Cavallari; Minoli A Perera
Journal: Future Cardiol Date: 2012-07

4. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.

Authors: David Villagra; Jorge Duconge; Andreas Windemuth; Carmen L Cadilla; Mohan Kocherla; Krystyna Gorowski; Kali Bogaard; Jessica Y Renta; Irelys A Cruz; Sara Mirabal; Richard L Seip; Gualberto Ruaño
Journal: Clin Chim Acta Date: 2010-05-19 Impact factor: 3.786

10. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

Authors: Danxin Wang; Huizi Chen; Kathryn M Momary; Larisa H Cavallari; Julie A Johnson; Wolfgang Sadée
Journal: Blood Date: 2008-06-03 Impact factor: 22.113

Population variation in VKORC1 haplotype structure.

Review 1. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

2. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Review 3. The future of warfarin pharmacogenetics in under-represented minority groups.

4. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.

5. The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.

Review 6. Pharmacogenomics in early-phase clinical development.

7. Predictors of unstable anticoagulation in African Americans.

Review 8. Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Review 9. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

10. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.